| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RDH11 |
| Uniprot No | Q8TC12 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-318aa |
| 氨基酸序列 | PQIRKMLSSGVCTSTVQLPGKVVVVTGANTGIGKETAKELAQRGARVYLACRDVEKGELVAKEIQTTTGNQQVLVRKLDLSDTKSIRAFAKGFLAEEKHLHVLINNAGVMMCPYSKTADGFEMHIGVNHLGHFLLTHLLLEKLKESAPSRIVNVSSLAHHLGRIHFHNLQGEKFYNAGLAYCHSKLANILFTQELARRLKGSGVTTYSVHPGTVQSELVRHSSFMRWMWWLFSFFIKTPQQGAQTSLHCALTEGLEILSGNHFSDCHVAWVSAQARNETIARRLWDVSCDLLGLPID |
| 预测分子量 | 49.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RDH11重组蛋白的参考文献示例(注：内容为模拟生成，仅供参考)：
---
1. **标题**：*"Characterization of Recombinant Human RDH11: Enzymatic Activity and Role in Retinoid Metabolism"*
**作者**：Haeseleer F, et al.
**摘要**：研究利用重组表达的RDH11蛋白，证实其催化全反式视黄醇氧化为视黄醛的能力，并揭示其在视网膜色素上皮细胞中的代谢调控作用。
2. **标题**：*"Structural Insights into RDH11 Substrate Specificity via Recombinant Protein Crystallography"*
**作者**：Wu BX, et al.
**摘要**：通过重组RDH11蛋白的晶体结构解析，阐明其底物结合口袋的关键氨基酸残基，解释了其对脂溶性维生素A衍生物的选择性催化机制。
3. **标题**：*"Recombinant RDH11 Expression in Cancer Cells: Implications for Cellular Retinol Homeostasis"*
**作者**：Kedishvili NY, et al.
**摘要**：研究重组RDH11在乳腺癌细胞中的过表达效应，发现其通过调节视黄酸水平抑制肿瘤增殖，提示其潜在的治疗靶点价值。
4. **标题**：*"Optimization of Recombinant RDH11 Production in E. coli for Functional Studies"*
**作者**：Kiser PD, et al.
**摘要**：报道一种高效表达和纯化重组RDH11蛋白的大肠杆菌系统，验证其酶活稳定性，为大规模生化研究提供可靠方法。
---
提示：实际文献需通过PubMed、Google Scholar等平台检索确认。
**Background of RDH11 Recombinant Protein**
Retinol dehydrogenase 11 (RDH11) is a member of the short-chain dehydrogenase/reductase (SDR) superfamily, which plays a critical role in retinoid metabolism. This enzyme is primarily involved in the oxidation of all-*trans*-retinol to all-*trans*-retinal, a key step in the visual cycle and cellular processes linked to vitamin A signaling. RDH11 is expressed in various tissues, including the retina, liver, and skin, highlighting its broad functional relevance. Unlike other RDH isoforms, RDH11 localizes to the endoplasmic reticulum and is implicated in non-photoreceptor retinoid pathways, suggesting roles in cellular differentiation, lipid metabolism, and homeostasis.
Recombinant RDH11 protein is engineered through heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable biochemical and functional studies. Purified RDH11 retains enzymatic activity, allowing researchers to explore its substrate specificity, kinetics, and interactions with cofactors like NADP+/NAD+. Structural studies using recombinant protein have provided insights into its catalytic mechanism and potential regulatory domains.
Dysregulation of RDH11 has been associated with metabolic disorders, retinal degeneration, and cancer progression. For instance, mutations in RDH11 may disrupt retinoid processing, contributing to vision defects or impaired cellular signaling. In cancer, altered RDH11 expression correlates with tumor cell proliferation and resistance to retinoid-based therapies.
The availability of recombinant RDH11 facilitates drug discovery, particularly in designing inhibitors or activators to modulate retinoid-related pathways. It also serves as a tool for diagnostic research, aiding in biomarker identification for diseases linked to vitamin A metabolism. Overall, RDH11 recombinant protein is a vital resource for unraveling the enzyme’s physiological roles and therapeutic potential.
×
